{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:09:36Z","timestamp":1789546176238,"version":"build-2803163510"},"reference-count":157,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007076","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["IG 20220 ID 24528"],"award-info":[{"award-number":["IG 20220 ID 24528"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bracco Imaging SpA","award":["DCM.AD003.144.001"],"award-info":[{"award-number":["DCM.AD003.144.001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Recently, prostate-specific membrane antigen (PSMA) has gained momentum in tumor nuclear molecular imaging as an excellent target for both the diagnosis and therapy of prostate cancer. Since 2008, after years of preclinical research efforts, a plentitude of radiolabeled compounds mainly based on low molecular weight PSMA inhibitors (PSMA-i) have been described for imaging and theranostic applications, and some of them have been transferred to the clinic. Most of these compounds include radiometals (e.g., 68Ga, 64Cu, 177Lu) for positron emission tomography (PET) imaging or endoradiotherapy. Nowadays, although the development of new PET tracers has caused a significant drop in single-photon emission tomography (SPECT) research programs and the development of new technetium-99m (99mTc) tracers is rare, this radionuclide remains the best atom for SPECT imaging owing to its ideal physical decay properties, convenient availability, and rich and versatile coordination chemistry. Indeed, 99mTc still plays a relevant role in diagnostic nuclear medicine, as the number of clinical examinations based on 99mTc outscores that of PET agents and 99mTc-PSMA SPECT\/CT may be a cost-effective alternative for 68Ga-PSMA PET\/CT. This review aims to give an overview of the specific features of the developed [99mTc]Tc-tagged PSMA agents with particular attention to [99mTc]Tc-PSMA-i. The chemical and pharmacological properties of the latter will be compared and discussed, highlighting the pros and cons with respect to [68Ga]Ga-PSMA11.<\/jats:p>","DOI":"10.3390\/molecules27092617","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T22:07:26Z","timestamp":1650406046000},"page":"2617","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["A Review on the Current State and Future Perspectives of [99mTc]Tc-Housed PSMA-i in Prostate Cancer"],"prefix":"10.3390","volume":"27","author":[{"given":"Sara","family":"Brunello","sequence":"first","affiliation":[{"name":"Institute of Condensed Matter Chemistry and Technologies for Energy ICMATE-CNR, Corso Stati Uniti 4, 35127 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9351-382X","authenticated-orcid":false,"given":"Nicola","family":"Salvarese","sequence":"additional","affiliation":[{"name":"Institute of Condensed Matter Chemistry and Technologies for Energy ICMATE-CNR, Corso Stati Uniti 4, 35127 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7002-1665","authenticated-orcid":false,"given":"Debora","family":"Carpanese","sequence":"additional","affiliation":[{"name":"Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35124 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Gobbi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0701-3616","authenticated-orcid":false,"given":"Laura","family":"Melendez-Alafort","sequence":"additional","affiliation":[{"name":"Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35124 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7919-516X","authenticated-orcid":false,"given":"Cristina","family":"Bolzati","sequence":"additional","affiliation":[{"name":"Institute of Condensed Matter Chemistry and Technologies for Energy ICMATE-CNR, Corso Stati Uniti 4, 35127 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"key":"ref_1","unstructured":"(2021, November 25). Cancer Today. Available online: http:\/\/gco.iarc.fr\/today\/home."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer Statistics for the Year 2020: An Overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"El Fakiri, M., Geis, N.M., Ayada, N., Eder, M., and Eder, A.C. (2021). PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives. Cancers, 13.","DOI":"10.3390\/cancers13163967"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/RLU.0000000000001991","article-title":"SPECT\/CT with the PSMA Ligand 99mTc-MIP-1404 for Whole-Body Primary Staging of Patients with Prostate Cancer","volume":"43","author":"Schmidkonz","year":"2018","journal-title":"Clin. Nucl. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/1078-0432.CCR-15-0820","article-title":"New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy","volume":"22","author":"Haberkorn","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and Prostate-Cancer Mortality in a Randomized European Study","volume":"360","author":"Hugosson","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","article-title":"Mortality Results from a Randomized Prostate-Cancer Screening Trial","volume":"360","author":"Berg","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_9","unstructured":"Professionals, S.-O. (2021, November 25). EAU Guidelines: Prostate Cancer. Available online: https:\/\/uroweb.org\/guideline\/prostate-cancer\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1373\/clinchem.2008.110668","article-title":"Emerging Biomarkers for the Diagnosis and Prognosis of Prostate Cancer","volume":"54","author":"Sardana","year":"2008","journal-title":"Clin. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.19.02757","article-title":"Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline","volume":"38","author":"Trabulsi","year":"2020","journal-title":"JCO"},{"key":"ref_12","first-page":"927","article-title":"Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients","volume":"7","author":"Horoszewicz","year":"1987","journal-title":"Anticancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/bju.13801","article-title":"Defining the Clinical Utility of PSMA-Targeted PET Imaging of Prostate Cancer","volume":"120","author":"Gorin","year":"2017","journal-title":"BJU Int."},{"key":"ref_14","first-page":"S13","article-title":"Overview of Prostate-Specific Membrane Antigen","volume":"6","author":"Chang","year":"2004","journal-title":"Rev. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1098-2388(200001\/02)18:1<10::AID-SSU3>3.0.CO;2-V","article-title":"Prostate-Specific Membrane Antigen (PSMA): Current Benefits and Future Value","volume":"18","author":"Elgamal","year":"2000","journal-title":"Semin. Surg. Oncol."},{"key":"ref_16","first-page":"7","article-title":"The Clinical Role of Prostate-Specific Membrane Antigen (PSMA)","volume":"7","author":"Chang","year":"2002","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.semnuclmed.2019.02.008","article-title":"PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy","volume":"49","author":"Wester","year":"2019","journal-title":"Semin. Nucl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1021\/mp900069d","article-title":"Prostate-Specific Membrane Antigen Targeted Imaging and Therapy of Prostate Cancer Using a PSMA Inhibitor as a Homing Ligand","volume":"6","author":"Kularatne","year":"2009","journal-title":"Mol. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"34930","DOI":"10.18632\/oncotarget.9004","article-title":"Heterogeneous PSMA Expression on Circulating Tumor Cells\u2014A Potential Basis for Stratification and Monitoring of PSMA-Directed Therapies in Prostate Cancer","volume":"7","author":"Gorges","year":"2016","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1874471012666190729151540","article-title":"Toward the Discovery and Development of PSMA Targeted Inhibitors for Nuclear Medicine Applications","volume":"13","author":"Sara","year":"2020","journal-title":"Curr. Radiopharm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/cmmi.1558","article-title":"Generation and Characterization of Nanobodies Targeting PSMA for Molecular Imaging of Prostate Cancer","volume":"9","author":"Evazalipour","year":"2014","journal-title":"Contrast Media Mol. Imaging"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/med.21508","article-title":"Targeting Prostate Cancer: Prostate-Specific Membrane Antigen Based Diagnosis and Therapy","volume":"39","author":"Haberkorn","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1158\/1078-0432.CCR-04-2690","article-title":"Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen: In Vivo Imaging in Experimental Models of Prostate Cancer","volume":"11","author":"Foss","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/CCO.0000000000000767","article-title":"Antibodies Targeting Prostate-Specific Membrane Antigen Positive Prostate Cancer: From Diagnostic Imaging to Theranostics","volume":"33","author":"Aoun","year":"2021","journal-title":"Curr. Opin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1021\/jm0306226","article-title":"Synthesis of Urea-Based Inhibitors as Active Site Probes of Glutamate Carboxypeptidase II: Efficacy as Analgesic Agents","volume":"47","author":"Kozikowski","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1053\/j.semnuclmed.2016.04.004","article-title":"Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer","volume":"46","author":"Kratochwil","year":"2016","journal-title":"Semin. Nucl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.nucmedbio.2016.08.006","article-title":"Radiolabeled Enzyme Inhibitors and Binding Agents Targeting PSMA: Effective Theranostic Tools for Imaging and Therapy of Prostate Cancer","volume":"43","author":"Pillai","year":"2016","journal-title":"Nucl. Med. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10967-019-06800-6","article-title":"Historical Review of Pharmacological Development and Dosimetry of PSMA-Based Theranostics for Prostate Cancer","volume":"322","author":"Vahidfar","year":"2019","journal-title":"J. Radioanal. Nucl. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Manafi-Farid, R., Ranjbar, S., Jamshidi Araghi, Z., Pilz, J., Schweighofer-Zwink, G., Pirich, C., and Beheshti, M. (2021). Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends. Cancers, 13.","DOI":"10.3390\/cancers13215360"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/wjnm.WJNM_54_17","article-title":"Nuclear Medicine in Prostate Cancer: A New Era for Radiotracers","volume":"17","author":"Cuccurullo","year":"2018","journal-title":"World J. Nucl. Med."},{"key":"ref_31","first-page":"455","article-title":"Imaging of Prostate Cancer with Positron Emission Tomography","volume":"17","author":"Zimmerman","year":"2019","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1536012118776068","article-title":"PSMA Theranostics: Current Status and Future Directions","volume":"17","author":"Rahbar","year":"2018","journal-title":"Mol. Imaging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1245\/s10434-018-6805-y","article-title":"The Value of 99mTc-PSMA SPECT\/CT-Guided Surgery for Identifying and Locating Lymph Node Metastasis in Prostate Cancer Patients","volume":"26","author":"Su","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.bmcl.2012.09.014","article-title":"Synthesis and SAR of 99mTc\/Re-Labeled Small Molecule Prostate Specific Membrane Antigen Inhibitors with Novel Polar Chelates","volume":"23","author":"Lu","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Gourni, E., and Henriksen, G. (2017). Metal-Based PSMA Radioligands. Molecules, 22.","DOI":"10.3390\/molecules22040523"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00259-013-2374-2","article-title":"PSMA as a Target for Radiolabelled Small Molecules","volume":"40","author":"Eder","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2967\/jnumed.120.260455","article-title":"68Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership","volume":"62","author":"Carlucci","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_38","first-page":"349","article-title":"[68Ga]Ga-PSMA-11 in Prostate Cancer: A Comprehensive Review","volume":"10","author":"Bois","year":"2020","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1200\/JCO.2019.37.7_suppl.68","article-title":"Is There a Correlation between Gleason Score and Maximum Standardized Uptake Value in Locally Advanced Prostate Cancer Patients?","volume":"37","author":"Cem","year":"2019","journal-title":"JCO"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Koerber, S.A., Boesch, J., Kratochwil, C., Schlampp, I., Ristau, J., Winter, E., Zschaebitz, S., Hofer, L., Herfarth, K., and Kopka, K. (2021). Predicting the Risk of Metastases by PSMA-PET\/CT\u2014Evaluation of 335 Men with Treatment-Na\u00efve Prostate Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13071508"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2967\/jnumed.120.245605","article-title":"68Ga-PSMA PET\/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer","volume":"62","author":"Klingenberg","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Lenzo, N., Meyrick, D., Turner, J., Lenzo, N.P., Meyrick, D., and Turner, J.H. (2018). Review of Gallium-68 PSMA PET\/CT Imaging in the Management of Prostate Cancer. Diagnostics, 8.","DOI":"10.3390\/diagnostics8010016"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/MNM.0000000000001233","article-title":"Optimization of the Radiosynthesis of [68Ga]Ga-PSMA-11 Using a Trasis MiniAiO Synthesizer: Do We Need to Heat and Purify?","volume":"41","author":"Reverchon","year":"2020","journal-title":"Nucl. Med. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13550-015-0147-6","article-title":"[111In]PSMA-I&T: Expanding the Spectrum of PSMA-I&T Applications towards SPECT and Radioguided Surgery","volume":"5","author":"Schottelius","year":"2015","journal-title":"EJNMMI Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00345-018-2200-3","article-title":"Novel Technology of Molecular Radio-Guidance for Lymph Node Dissection in Recurrent Prostate Cancer by PSMA-Ligands","volume":"36","author":"Rauscher","year":"2018","journal-title":"World J. Urol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1007\/s00259-008-0814-1","article-title":"Is PET Always an Advantage versus Planar and SPECT Imaging?","volume":"35","author":"Mariani","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1021\/cr1000755","article-title":"Technetium and Gallium Derived Radiopharmaceuticals: Comparing and Contrasting the Chemistry of Two Important Radiometals for the Molecular Imaging Era","volume":"110","author":"Louie","year":"2010","journal-title":"Chem. Rev."},{"key":"ref_48","first-page":"1","article-title":"Normal Variants, Pitfalls, and Artifacts in Ga-68 Prostate Specific Membrane Antigen (PSMA) PET\/CT Imaging","volume":"2","author":"Malan","year":"2022","journal-title":"Front. Nucl. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1007\/s00259-021-05433-w","article-title":"PSMA Radioligand Therapy for Solid Tumors Other than Prostate Cancer: Background, Opportunities, Challenges, and First Clinical Reports","volume":"48","author":"Uijen","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.pgp.0000225386.41244.bd","article-title":"Prostate-Derived Ets Factor Is Overexpressed in Serous Epithelial Ovarian Tumors","volume":"26","author":"Rodabaugh","year":"2007","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.juro.2017.08.079","article-title":"Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role","volume":"199","author":"Spatz","year":"2018","journal-title":"J. Urol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/apm.12195","article-title":"Prostate-Specific Membrane Antigen Expression in Tumor-Associated Vasculature of Breast Cancers","volume":"122","author":"Wernicke","year":"2014","journal-title":"APMIS"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.prp.2014.06.024","article-title":"CEACAM5 Has Different Expression Patterns in Gastric Non-Neoplastic and Neoplastic Lesions and Cytoplasmic Staining Is a Marker for Evaluation of Tumor Progression in Gastric Adenocarcinoma","volume":"210","author":"Liu","year":"2014","journal-title":"Pathol. Res. Pract."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Schmidt, L.H., Heitk\u00f6tter, B., Schulze, A.B., Schliemann, C., Steinestel, K., Trautmann, M., Marra, A., Hillejan, L., Mohr, M., and Evers, G. (2017). Prostate Specific Membrane Antigen (PSMA) Expression in Non-Small Cell Lung Cancer. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0186280"},{"key":"ref_55","first-page":"2674","article-title":"Prostate-Specific Membrane Antigen Is Produced in Tumor-Associated Neovasculature","volume":"5","author":"Chang","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"ref_56","first-page":"3192","article-title":"Five Different Anti-Prostate-Specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-Associated Neovasculature","volume":"59","author":"Chang","year":"1999","journal-title":"Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1475-2867-14-26","article-title":"Prostate Specific Membrane Antigen (PSMA) Expression in Primary Gliomas and Breast Cancer Brain Metastases","volume":"14","author":"Nomura","year":"2014","journal-title":"Cancer Cell. Int."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"45","DOI":"10.30699\/ijp.13.1.45","article-title":"Expression of Prostate-Specific Membrane Antigen (PSMA) in Brain Glioma and Its Correlation with Tumor Grade","volume":"13","author":"Saffar","year":"2018","journal-title":"Iran. J. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/abr.abr_209_18","article-title":"Prostate-Specific Membrane Antigen Expression in Neovasculature of Glioblastoma Multiforme","volume":"8","author":"Mahzouni","year":"2019","journal-title":"Adv. Biomed. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1097\/RLU.0000000000001769","article-title":"Prostate-Specific Membrane Antigen\u2013Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas","volume":"42","author":"Fragomeni","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/RLU.0000000000001451","article-title":"Diagnostic Value of 68Ga PSMA-11 PET\/CT Imaging of Brain Tumors\u2014Preliminary Analysis","volume":"42","author":"Sasikumar","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.radonc.2020.09.034","article-title":"The Tubarial Salivary Glands: A Potential New Organ at Risk for Radiotherapy","volume":"154","author":"Valstar","year":"2021","journal-title":"Radiother. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.neuroscience.2006.10.022","article-title":"Expression of Glutamate Carboxypeptidase II in Human Brain","volume":"144","author":"Hilgert","year":"2007","journal-title":"Neuroscience"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2559.2007.02635.x","article-title":"Prostate-Specific Membrane Antigen (PSMA) Protein Expression in Normal and Neoplastic Tissues and Its Sensitivity and Specificity in Prostate Adenocarcinoma: An Immunohistochemical Study Using Mutiple Tumour Tissue Microarray Technique","volume":"50","author":"Zhang","year":"2007","journal-title":"Histopathology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00259-018-4135-8","article-title":"Initial Clinical Experience Performing Sialendoscopy for Salivary Gland Protection in Patients Undergoing 225Ac-PSMA-617 RLT","volume":"46","author":"Rathke","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s13139-017-0508-3","article-title":"Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: An Empirical Proof of a Promising Concept","volume":"52","author":"Baum","year":"2018","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.2967\/jnumed.118.215350","article-title":"xois Monosodium Glutamate Reduces 68Ga-PSMA-11 Uptake in Salivary Glands and Kidneys in a Preclinical Prostate Cancer Model","volume":"59","author":"Rousseau","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Nedelcovych, M.T., Dash, R.P., Wu, Y., Choi, E.Y., Lapidus, R.S., Majer, P., Abou, D., Penet, M.-F., Nikolopoulou, A., and Amor-Coarasa, A. (2019). JHU-2545 Selectively Shields Salivary Glands and Kidneys during PSMA-Targeted Radiotherapy. bioRxiv.","DOI":"10.1101\/457085"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40336-018-0264-0","article-title":"Advances in Clinical Molecular Imaging Instrumentation","volume":"6","author":"Hutton","year":"2018","journal-title":"Clin. Transl. Imaging"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.pcad.2015.02.002","article-title":"Advances in SPECT and PET Hardware","volume":"57","author":"Slomka","year":"2015","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2174\/187152012800617821","article-title":"Chelating Systems for 99mTc\/188Re in the Development of Radiolabeled Peptide Pharmaceuticals","volume":"12","author":"Bolzati","year":"2012","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.2174\/092986710791859388","article-title":"99mTc-Radiolabelled Peptides for Tumour Imaging: Present and Future","volume":"17","author":"Bolzati","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.nucmedbio.2020.05.005","article-title":"Review on 99mTc Radiopharmaceuticals with Emphasis on New Advancements","volume":"92","author":"Duatti","year":"2020","journal-title":"Nucl. Med. Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"7032","DOI":"10.2174\/0929867327666191223121211","article-title":"Radiolabeled Protein-Inhibitor Peptides with Rapid Clinical Translation towards Imaging and Therapy","volume":"27","author":"Guillermina","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2533\/chimia.2020.953","article-title":"Bioorganometallic Technetium and Rhenium Chemistry: Fundamentals for Applications","volume":"74","author":"Alberto","year":"2020","journal-title":"CHIMIA Int. J. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"213869","DOI":"10.1016\/j.ccr.2021.213869","article-title":"Bioorganometallics: 99mTc Cytectrenes, Syntheses and Applications in Nuclear Medicine","volume":"437","author":"Lengacher","year":"2021","journal-title":"Coord. Chem. Rev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1002\/cbic.202000387","article-title":"The \u201cCarbonyl Story\u201d and Beyond; Experiences, Lessons and Implications","volume":"21","author":"Alberto","year":"2020","journal-title":"ChemBioChem"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ica.2010.01.009","article-title":"Hydrazinonicotinic Acid (HYNIC)\u2014Coordination Chemistry and Applications in Radiopharmaceutical Chemistry","volume":"363","author":"Meszaros","year":"2010","journal-title":"Inorg. Chim. Acta"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Bolzati, C., and Dolmella, A. (2020). Nitrido Technetium\u201399m Core in Radiopharmaceutical Applications: Four Decades of Research. Inorganics, 8.","DOI":"10.3390\/inorganics8010003"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1021\/bc900493e","article-title":"Biological In Vitro and In Vivo Studies of a Series of New Asymmetrical Cationic [99mTc(N)(DTC-Ln)(PNP)]+ Complex (DTC-Ln = Alicyclic Dithiocarbamate and PNP = Diphosphinoamine)","volume":"21","author":"Bolzati","year":"2010","journal-title":"Bioconjugate Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"11114","DOI":"10.1021\/acs.jmedchem.8b01191","article-title":"[99mTc][Tc(N)(DASD)(PNPn)]+ (DASD = 1,4-Dioxa-8-Azaspiro[4,5]Decandithiocarbamate, PNPn = Bisphosphinoamine) for Myocardial Imaging: Synthesis, Pharmacological and Pharmacokinetic Studies","volume":"61","author":"Salvarese","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"9596","DOI":"10.1021\/acs.jmedchem.8b01075","article-title":"[99mTc][Tc(N)PNP43]-Labeled RGD Peptides As New Probes for a Selective Detection of Av\u03b23 Integrin: Synthesis, Structure\u2013Activity and Pharmacokinetic Studies","volume":"61","author":"Bolzati","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1021\/acs.molpharmaceut.1c00816","article-title":"Water-Soluble [Tc(N)(PNP)] Moiety for Room-Temperature 99mTc Labeling of Sensitive Target Vectors","volume":"19","author":"Bolzati","year":"2022","journal-title":"Mol. Pharm."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1039\/c0dt01462a","article-title":"99mTc-Centered One-Pot Synthesis for Preparation of 99mTc Radiotracers","volume":"40","author":"Liu","year":"2011","journal-title":"Dalton Trans."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/cmdc.201800110","article-title":"Synthesis, Characterization, and Initial Biological Evaluation of [99mTc]Tc-Tricarbonyl-Labeled DPA-\u03b1-MSH Peptide Derivatives for Potential Melanoma Imaging","volume":"13","author":"Gao","year":"2018","journal-title":"ChemMedChem"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.nucmedbio.2007.04.006","article-title":"Avidin\u2013Biotin System: A Small Library of Cysteine Biotinylated Derivatives Designed for the [99mTc(N)(PNP)]2+ Metal Fragment","volume":"34","author":"Bolzati","year":"2007","journal-title":"Nucl. Med. Biol."},{"key":"ref_87","first-page":"610","article-title":"Radiolabeled Monoclonal Antibodies Specific to the Extracellular Domain of Prostate-Specific Membrane Antigen: Preclinical Studies in Nude Mice Bearing LNCaP Human Prostate Tumor","volume":"44","author":"Vallabhajosula","year":"2003","journal-title":"J. Nucl. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/j.1464-410X.2005.05511.x","article-title":"Imaging with Radiolabelled Monoclonal Antibody (MUJ591) to Prostate-Specific Membrane Antigen in Staging of Clinically Localized Prostatic Carcinoma: Comparison with Clinical, Surgical and Histological Staging","volume":"95","author":"Nargund","year":"2005","journal-title":"BJU Int."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Bolzati, C., and Spolaore, B. (2021). Enzymatic Methods for the Site-Specific Radiolabeling of Targeting Proteins. Molecules, 26.","DOI":"10.3390\/molecules26123492"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2191-219X-4-13","article-title":"Design and Preclinical Evaluation of a 99mTc-Labelled Diabody of MAb J591 for SPECT Imaging of Prostate-Specific Membrane Antigen (PSMA)","volume":"4","author":"Kampmeier","year":"2014","journal-title":"EJNMMI Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.pep.2013.02.016","article-title":"Design, Production, and Characterization of a Single-Chain Variable Fragment (ScFv) Derived from the Prostate Specific Membrane Antigen (PSMA) Monoclonal Antibody J591","volume":"89","author":"Parker","year":"2013","journal-title":"Protein Expr. Purif."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/MNM.0000000000000698","article-title":"A 99mTc-Labelled ScFv Antibody Fragment That Binds to Prostate-Specific Membrane Antigen","volume":"38","author":"Nawaz","year":"2017","journal-title":"Nucl. Med. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1021\/acs.bioconjchem.0c00561","article-title":"Optimal His-Tag Design for Efficient [99mTc(CO)3]+ and [188Re(CO)3]+ Labeling of Proteins for Molecular Imaging and Radionuclide Therapy by Analysis of Peptide Arrays","volume":"32","author":"Williams","year":"2020","journal-title":"Bioconjugate Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"035008","DOI":"10.1088\/2043-6262\/ac2747","article-title":"D2B Antibody and Its ScFvD2B Fragment in Nanomedicine: Promising Tools in the Theranostics of Prostate Cancer","volume":"12","author":"Mitri","year":"2021","journal-title":"Adv. Nat. Sci. Nanosci. Nanotechnol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"9313","DOI":"10.1038\/s41598-020-66285-2","article-title":"Development of 177 Lu-ScFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen","volume":"10","author":"Carpanese","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1002\/mp.14936","article-title":"Preclinical Dosimetric Studies of 177Lu-ScFvD2B and Comparison with 177Lu-PSMA-617 and 177Lu-IPSMA Endoradiotherapeutic Agents","volume":"48","author":"Turato","year":"2021","journal-title":"Med. Phys."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nbt1223","article-title":"Cell Type\u2013Specific Delivery of SiRNAs with Aptamer-SiRNA Chimeras","volume":"24","author":"McNamara","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.nucmedbio.2021.11.003","article-title":"Molecular Imaging and Treatment of PSMA-Positive Prostate Cancer with 99mTc Radiolabeled Aptamer-SiRNA Chimeras","volume":"104\u2013105","author":"Jiao","year":"2022","journal-title":"Nucl. Med. Biol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.2174\/092986711797189691","article-title":"Molecular Imaging with Nucleic Acid Aptamers","volume":"18","author":"Hong","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"ref_100","first-page":"78","article-title":"Aptamers and Apple Pies: A Mini-Review of PSMA Aptamers and Lessons from Donald S. Coffey","volume":"6","author":"Lupold","year":"2018","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/pros.21493","article-title":"A Phosphoramidate-Based Prostate-Specific Membrane Antigen-Targeted SPECT Agent","volume":"72","author":"Jabbes","year":"2012","journal-title":"Prostate"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/pros.22575","article-title":"PSMA-Targeted SPECT Agents: Mode of Binding Effect on in Vitro Performance","volume":"73","author":"Moore","year":"2013","journal-title":"Prostate"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.2967\/jnumed.107.040303","article-title":"Production of Multimeric Prostate-Specific Membrane Antigen Small-Molecule Radiotracers Using a Solid-Phase 99mTc Preloading Strategy","volume":"48","author":"Misra","year":"2007","journal-title":"J. Nucl. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"17S","DOI":"10.2967\/jnumed.116.186775","article-title":"Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned during the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers","volume":"58","author":"Kopka","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1021\/jm800111u","article-title":"Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA)","volume":"51","author":"Banerjee","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1021\/jm400823w","article-title":"Effect of Chelators on the Pharmacokinetics of 99mTc-Labeled Imaging Agents for the Prostate-Specific Membrane Antigen (PSMA)","volume":"56","author":"Banerjee","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.2967\/jnumed.112.116624","article-title":"99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer","volume":"54","author":"Hillier","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_108","first-page":"523","article-title":"Development of a Simple Kit for Tc-99m-MIP-1404, a Single Amino Acid Chelate (SAAC II) Derived Small Molecule Inhibitor of Prostate Specific Membrane Antigen (PSMA) for Imaging Prostate Cancer","volume":"53","author":"Maresca","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.nucmedbio.2017.01.010","article-title":"99mTc-Labeling and Evaluation of a HYNIC Modified Small-Molecular Inhibitor of Prostate-Specific Membrane Antigen","volume":"48","author":"Xu","year":"2017","journal-title":"Nucl. Med. Biol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"103743","DOI":"10.1016\/j.bioorg.2020.103743","article-title":"Design, Synthesis, Radiolabeling and Biological Evaluation of New Urea-Based Peptides Targeting Prostate Specific Membrane Antigen","volume":"99","author":"Mosayebnia","year":"2020","journal-title":"Bioorg. Chem."},{"key":"ref_111","unstructured":"Sikora, A.E., Maurin, M., Jaron, A.W.O., Pijarowska-Kruszyna, J., Owska, M.O., Janota, B., Radzik, M., and Garnuszek, P. (2020). PSMA Inhibitor Derivatives for Labelling with 99mTc via Hynic, a Radiopharmaceutical Kit, Radiopharmaceutical Preparations and Their Use in Prostate Cancer Diagnostics. (EP3721907A1), Patent."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1073\/pnas.0502101102","article-title":"Crystal Structure of Prostate-Specific Membrane Antigen, a Tumor Marker and Peptidase","volume":"102","author":"Davis","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/sj.emboj.7600969","article-title":"Structure of Glutamate Carboxypeptidase II, a Drug Target in Neuronal Damage and Prostate Cancer","volume":"25","author":"Mesters","year":"2006","journal-title":"EMBO J."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2174\/092986712799462667","article-title":"Glutamate Carboxypeptidase II: An Overview of Structural Studies and Their Importance for Structure-Based Drug Design and Deciphering the Reaction Mechanism of the Enzyme","volume":"19","author":"Pavlicek","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2967\/jnumed.116.178939","article-title":"Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer","volume":"58","author":"Robu","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1021\/mp9000712","article-title":"Design, Synthesis, and Preclinical Evaluation of Prostate-Specific Membrane Antigen Targeted 99mTc-Radioimaging Agents","volume":"6","author":"Kularatne","year":"2009","journal-title":"Mol. Pharm."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nucmedbio.2017.01.012","article-title":"Clinical Translation of a PSMA Inhibitor for 99mTc-Based SPECT","volume":"48","author":"Davanzo","year":"2017","journal-title":"Nucl. Med. Biol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Lodhi, N.A., Park, J.Y., Kim, K., Hong, M.K., Kim, Y.J., Lee, Y.-S., Cheon, G.J., Kang, K.W., and Jeong, J.M. (2020). Synthesis and Evaluation of 99mTc-Tricabonyl Labeled Isonitrile Conjugates for Prostate-Specific Membrane Antigen (PSMA) Image. Inorganics, 8.","DOI":"10.3390\/inorganics8010005"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Xiao, D., Duan, X., Gan, Q., Zhang, X., and Zhang, J. (2020). Preparation and Biological Evaluation of [99mTc]Tc-CNGU as a PSMA-Targeted Radiotracer for the Imaging of Prostate Cancer. Molecules, 25.","DOI":"10.3390\/molecules25235548"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.2967\/jnumed.110.086751","article-title":"123I-MIP-1072, a Small-Molecule Inhibitor of Prostate-Specific Membrane Antigen, Is Effective at Monitoring Tumor Response to Taxane Therapy","volume":"52","author":"Hillier","year":"2011","journal-title":"J. Nucl. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1021\/acs.jmedchem.6b00024","article-title":"Purification-Free Method for Preparing Technetium-99m-Labeled Multivalent Probes for Enhanced in Vivo Imaging of Saturable Systems","volume":"59","author":"Mizuno","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/1389557516666160808122335","article-title":"The Influence of Co-Ligands on Improving Tumor Targeting of 99mTc-HYNIC Conjugated Peptides","volume":"17","author":"Torabizadeh","year":"2017","journal-title":"Mini-Rev. Med. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2217\/fon-2019-0635","article-title":"Functionalized Nano-Targeted Moieties in Management of Prostate Cancer","volume":"16","author":"Salaheldin","year":"2020","journal-title":"Future Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40336-018-0283-x","article-title":"Radiolabelled Nanoparticles for Cancer Diagnosis","volume":"6","author":"Varani","year":"2018","journal-title":"Clin. Transl. Imaging"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Mushtaq, S., Bibi, A., Park, J.E., and Jeon, J. (2021). Recent Progress in Technetium-99m-Labeled Nanoparticles for Molecular Imaging and Cancer Therapy. Nanomaterials, 11.","DOI":"10.3390\/nano11113022"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"6090","DOI":"10.1002\/chem.201405704","article-title":"99mTc Radiolabeling and Biological Evaluation of Nanoparticles Functionalized with a Versatile Coating Ligand","volume":"21","author":"Felber","year":"2015","journal-title":"Chem. Eur. J."},{"key":"ref_127","unstructured":"(2021, October 28). Home\u2014ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_128","first-page":"473","article-title":"Clinical Application of SPECT-CT Imaging with 99mTc\/PSMA T4 in Patients with Recurrent Prostate Cancer","volume":"61","author":"Sergieva","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.2967\/jnumed.114.140426","article-title":"99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer","volume":"55","author":"Vallabhajosula","year":"2014","journal-title":"J. Nucl. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2967\/jnumed.116.187807","article-title":"Phase 2 Study of 99m Tc-Trofolastat SPECT\/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection","volume":"58","author":"Goffin","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2967\/jnumed.117.200220","article-title":"Intraindividual Comparison of 99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand 99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer","volume":"59","author":"Rathke","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/RLU.0000000000002880","article-title":"99mTc-MIP-1404 SPECT\/CT for Patients with Metastatic Prostate Cancer: Interobserver and Intraobserver Variability in Treatment-Related Longitudinal Tracer Uptake Assessments of Prostate-Specific Membrane Antigen-Positive Lesions","volume":"45","author":"Schmidkonz","year":"2020","journal-title":"Clin. Nucl. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/pros.23444","article-title":"99mTc-MIP-1404-SPECT\/CT for the Detection of PSMA-Positive Lesions in 225 Patients with Biochemical Recurrence of Prostate Cancer","volume":"78","author":"Schmidkonz","year":"2018","journal-title":"Prostate"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/RLU.0000000000001433","article-title":"First Experience with SPECT\/CT Using a 99mTc-Labeled Inhibitor for Prostate-Specific Membrane Antigen in Patients with Biochemical Recurrence of Prostate Cancer","volume":"42","author":"Reinfelder","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1097\/RLU.0000000000003102","article-title":"99mTc-MIP-1404 SPECT\/CT for Assessment of Whole-Body Tumor Burden and Treatment Response in Patients with Biochemical Recurrence of Prostate Cancer","volume":"45","author":"Schmidkonz","year":"2020","journal-title":"Clin. Nucl. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s12149-019-01400-6","article-title":"PSMA SPECT\/CT with 99mTc-MIP-1404 in Biochemical Recurrence of Prostate Cancer: Predictive Factors and Efficacy for the Detection of PSMA-Positive Lesions at Low and Very-Low PSA Levels","volume":"33","author":"Schmidkonz","year":"2019","journal-title":"Ann. Nucl. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.eururo.2018.03.013","article-title":"99mTechnetium-Based Prostate-Specific Membrane Antigen\u2013Radioguided Surgery in Recurrent Prostate Cancer","volume":"75","author":"Maurer","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13550-021-00762-1","article-title":"99mTc-Labelled PSMA Ligand for Radio-Guided Surgery in Nodal Metastatic Prostate Cancer: Proof of Principle","volume":"11","author":"Mix","year":"2021","journal-title":"EJNMMI Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13550-020-00635-z","article-title":"[99cmTc]Tc-PSMA-I&S-SPECT\/CT: Experience in Prostate Cancer Imaging in an Outpatient Center","volume":"10","author":"Werner","year":"2020","journal-title":"EJNMMI Res."},{"key":"ref_140","first-page":"1","article-title":"Direct Comparison of 99mTc-PSMA SPECT\/CT and 68Ga-PSMA PET\/CT in Patients with Prostate Cancer","volume":"8","author":"Albalooshi","year":"2020","journal-title":"Asia Ocean. J. Nucl. Med. Biol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2017.05.005","article-title":"99mTc-Labeled PSMA Inhibitor: Biokinetics and Radiation Dosimetry in Healthy Subjects and Imaging of Prostate Cancer Tumors in Patients","volume":"52","author":"Davanzo","year":"2017","journal-title":"Nucl. Med. Biol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/pros.23379","article-title":"Diagnostic Sensitivity of Tc-99m HYNIC PSMA SPECT\/CT in Prostate Carcinoma: A Comparative Analysis with Ga-68 PSMA PET\/CT","volume":"77","author":"Lawal","year":"2017","journal-title":"Prostate"},{"key":"ref_143","first-page":"332","article-title":"Head to Head Comparison Performance of 99mTc-EDDA\/HYNIC-IPSMA SPECT\/CT and 68Ga-PSMA-11 PET\/CT a Prospective Study in Biochemical Recurrence Prostate Cancer Patients","volume":"8","author":"Davanzo","year":"2018","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/RLU.0000000000003702","article-title":"Comparing 99mTc-PSMA to 99mTc-MDP in Prostate Cancer Staging of the Skeletal System","volume":"46","author":"Kabunda","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"ref_145","first-page":"1","article-title":"[99mTc]Tc-IPSMA SPECT Brain Imaging as a Potential Specific Diagnosis of Metastatic Brain Tumors and High-Grade Gliomas","volume":"96\u201397","year":"2021","journal-title":"Nucl. Med. Biol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1097\/RLU.0000000000003410","article-title":"99mTc-PSMA SPECT\/CT Versus 68Ga-PSMA PET\/CT in the Evaluation of Metastatic Prostate Cancer","volume":"46","author":"Fallahi","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/pros.23696","article-title":"Relationship between PSA Kinetics and Tc-99m HYNIC PSMA SPECT\/CT Detection Rates of Biochemical Recurrence in Patients with Prostate Cancer after Radical Prostatectomy","volume":"78","author":"Liu","year":"2018","journal-title":"Prostate"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4103\/1008-682X.192638","article-title":"Evaluation of 99mTc-Labeled PSMA-SPECT\/CT Imaging in Prostate Cancer Patients Who Have Undergone Biochemical Relapse","volume":"19","author":"Su","year":"2017","journal-title":"Asian J. Androl."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.2147\/CMAR.S285167","article-title":"Combination of 99mTc-Labeled PSMA-SPECT\/CT and Diffusion-Weighted MRI in the Prediction of Early Response After Carbon Ion Therapy in Prostate Cancer: A Non-Randomized Prospective Pilot Study","volume":"13","author":"Li","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"\u0106wik\u0142a, J.B., Roslan, M., Skoneczna, I., Kempi\u0144ska-Wr\u00f3bel, M., Maurin, M., Rogowski, W., Janota, B., Szarowicz, A., and Garnuszek, P. (2021). Initial Experience of Clinical Use of [99mTc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study. Pharmaceuticals, 14.","DOI":"10.3390\/ph14111107"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"70","DOI":"10.5603\/NMR.2021.0018","article-title":"SPECT-CT Imaging with [99mTc]PSMA-T4 in Patients with Recurrent Prostate Cancer","volume":"24","author":"Sergieva","year":"2021","journal-title":"Nucl. Med. Rev."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/MNM.0000000000001361","article-title":"Comparison of the Diagnostic Utility of 99mTc-PSMA Scintigraphy versus 68Ga-PSMA-11 PET\/CT in the Detection of Metastatic Prostate Cancer and Dosimetry Analysis: A Gamma-Camera-Based Alternate Prostate-Specific Membrane Antigen Imaging Modality","volume":"42","author":"Singh","year":"2021","journal-title":"Nucl. Med. Commun."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1021\/bc4005377","article-title":"Heterobivalent Agents Targeting PSMA and Integrin-Av\u03b23","volume":"25","author":"Shallal","year":"2014","journal-title":"Bioconjugate Chem."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"113752","DOI":"10.1016\/j.ejmech.2021.113752","article-title":"PSMA-Targeted Low-Molecular Double Conjugates for Diagnostics and Therapy","volume":"225","author":"Petrov","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2967\/jnumed.119.234922","article-title":"Radiohybrid Ligands: A Novel Tracer Concept Exemplified by 18F- or 68Ga-Labeled RhPSMA Inhibitors","volume":"61","author":"Wurzer","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"263371","DOI":"10.2967\/jnumed.121.263371","article-title":"Synthesis and Preclinical Evaluation of 177Lu-Labeled Radiohybrid PSMA Ligands (RhPSMAs) for Endoradiotherapy of Prostate Cancer","volume":"63","author":"Wurzer","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2967\/jnumed.119.233064","article-title":"Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen: Tuning Pharmacokinetic Properties and Exploring Dye\u2013Protein Interaction","volume":"61","author":"Hensbergen","year":"2020","journal-title":"J. Nucl. Med."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/9\/2617\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:56:40Z","timestamp":1760137000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/9\/2617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":157,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["molecules27092617"],"URL":"https:\/\/doi.org\/10.3390\/molecules27092617","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,19]]}}}